To determine the therapeutic potential of panobinostat on MS, panobinostat (30 mg/kg) was administrated daily in a classical myelin oligodendrocyte glycoprotein (MOG)-induced EAE mouse model, beginning on day 13 after immunization. This evidence concerns the gene MOG and myeloid sarcoma.